---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002673"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T15:01:33.080908+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024

## Summary
- Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.
- Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.
- Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.
- Levitz's separation includes continued salary through year-end and a general release of claims.

## SEC filing metadata
- accession: 0001171843-24-002673
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/f8k_050824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002673
- JSON: https://secwatch.observer/filing/0001171843-24-002673.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002673.txt

## Key facts
- Executive change
  Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Financial Officer and Treasurer
  source text: who tendered his resignation on May 2, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm
- Executive change
  Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer and Treasurer
  source text: announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.